Genetically Guided Pharmacotherapy for Structural Neurovascular Lesions.

Area of Science:

• Neuroscience
• Genetics
• Vascular Biology

Background:

• Structural neurovascular lesions (SNVLs), including arteriovenous malformations, have traditionally been treated with surgery, radiation, or endovascular methods.
• Treatment limitations due to lesion size, location, and complex angioarchitecture exclude many patients.
• Recent advances identify SNVLs as dynamic, genetically driven conditions often caused by somatic variants.

Purpose of the Study:

• To synthesize current research on pharmacologic treatments for SNVLs.
• To propose a genetically driven taxonomy for guiding targeted therapeutic selection.
• To highlight the potential of variant-specific or pathway-modulating therapies in clinical trials.

Main Methods:

• Review and synthesis of existing literature on SNVLs, genetics, and pharmacology.
• Analysis of SNVL-causing variants and their potential as drug targets.
• Consideration of molecular diagnosis, cerebrovascular biology, and outcome measures for future trials.

Main Results:

• Many SNVL-causing genetic variants are also oncogenic and represent active drug targets.
• A genetic classification of SNVLs can guide the selection of targeted pharmacologic treatments.
• Pharmacologic strategies offer potential new treatment options for select SNVL patients.

Conclusions:

• Pharmacologic treatments represent a promising frontier for managing structural neurovascular lesions.
• Targeted therapies based on specific genetic variants or modulated pathways warrant investigation.
• Future clinical trials should integrate molecular diagnostics and outcome measures to evaluate these novel treatments.